Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel small-molecule and antibody-based therapies that modulate the tumor microenvironment to improve outcomes for patients with cancer. The company operates within the biopharmaceutical and oncology drug development industries, with a strategic emphasis on immuno-oncology and targeted cancer therapies.
The company’s primary value driver is its pipeline of investigational oncology candidates, led by therapies designed to enhance anti-tumor immune responses and address mechanisms of resistance to existing treatments. Tempest Therapeutics was founded in 2011 and has evolved from an early research-focused entity into a publicly traded clinical-stage company following its initial public offering in 2021. Its strategy centers on advancing differentiated assets through clinical development, either independently or in collaboration with larger pharmaceutical partners.
Business Operations
Tempest Therapeutics operates as a single-reportable-segment biotechnology company, generating no product revenue and relying primarily on equity financing, collaboration payments, and grants to fund operations. Its core business activities include drug discovery, preclinical research, clinical trial execution, and regulatory development for oncology indications.
The company’s leading clinical assets include TPST-1120, a PPARα antagonist evaluated in combination with other cancer therapies, and TPST-1495, a dual-targeting monoclonal antibody designed to inhibit immunosuppressive signaling pathways. Tempest conducts clinical trials primarily through contracted research organizations and academic institutions, while maintaining internal capabilities in translational science and clinical strategy. As of public disclosures, the company does not report revenue-generating subsidiaries or commercial-stage products.
Strategic Position & Investments
Tempest Therapeutics’ strategic direction is centered on leveraging insights into tumor biology and immune regulation to develop combination therapies that can improve the efficacy of existing cancer treatments. Growth initiatives are focused on advancing its lead candidates through mid-stage clinical trials, particularly in indications with high unmet medical need such as hepatocellular carcinoma and other solid tumors.
The company has pursued selective partnerships and licensing arrangements to enhance development capabilities and share risk, including collaborations related to clinical evaluation of combination regimens. Tempest has not disclosed material acquisitions of commercial-stage companies; instead, its investments are primarily internal, directed toward pipeline expansion and clinical data generation. Emerging areas of focus include immune metabolism and resistance mechanisms within the tumor microenvironment.
Geographic Footprint
Tempest Therapeutics is headquartered in the United States, with its principal executive offices located in Brisbane, California. Its operational footprint is primarily U.S.-based, reflecting its status as a development-stage biotechnology company.
Internationally, the company maintains a limited but meaningful presence through the conduct of clinical trials in North America, Europe, and other regions as required for patient enrollment and regulatory strategy. These international activities are conducted through clinical research partners rather than wholly owned foreign operations, providing global reach without a large physical infrastructure.
Leadership & Governance
Tempest Therapeutics is led by an executive team with experience in oncology drug development, clinical research, and biotechnology company leadership. The leadership philosophy emphasizes scientific rigor, disciplined capital allocation, and strategic collaboration to advance innovative cancer therapies efficiently.
Key executives include:
- Stephen Brady – President and Chief Executive Officer
- Kevin Huang – Chief Financial Officer
- Sam Whiting – Chief Medical Officer
- Erin O’Rourke – General Counsel and Corporate Secretary
The company is governed by a board of directors composed of industry executives and scientific leaders who provide oversight on strategy, risk management, and shareholder interests, consistent with U.S. public company governance standards.